| 000 | 01624 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250516130205.0 | ||
| 264 | 0 | _c20141013 | |
| 008 | 201410s 0 0 eng d | ||
| 022 | _a1437-160X | ||
| 024 | 7 |
_a10.1007/s00296-012-2633-8 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRokutanda, Ryo | |
| 245 | 0 | 0 |
_aSafety and efficacy of mizoribine in patients with connective tissue diseases other than rheumatoid arthritis. _h[electronic resource] |
| 260 |
_bRheumatology international _cJan 2014 |
||
| 300 |
_a59-62 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAdrenal Cortex Hormones _xtherapeutic use |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aConnective Tissue Diseases _xdrug therapy |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 |
_aEnzyme Inhibitors _xadverse effects |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIMP Dehydrogenase _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xadverse effects |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 |
_aRibonucleosides _xadverse effects |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aKishimoto, Mitsumasa | |
| 700 | 1 | _aOhde, Sachiko | |
| 700 | 1 | _aShimizu, Hisanori | |
| 700 | 1 | _aNomura, Atsushi | |
| 700 | 1 | _aSuyama, Yasuhiro | |
| 700 | 1 | _aOhara, Yuri | |
| 700 | 1 | _aYamaguchi, Kenichi | |
| 700 | 1 | _aOkada, Masato | |
| 773 | 0 |
_tRheumatology international _gvol. 34 _gno. 1 _gp. 59-62 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s00296-012-2633-8 _zAvailable from publisher's website |
| 999 |
_c22387514 _d22387514 |
||